Back to Top Skip to main content

'Fused' technologies give 3D view of prostate during biopsy

Eisenhower Army Medical Center graphic Eisenhower Army Medical Center graphic

Recommended Content:

Men's Health | Military Hospitals and Clinics | Preventive Health

FORT GORDON, Ga. — A high-tech procedure that makes prostate biopsy more accurate and thorough is being rolled out at Eisenhower Army Medical Center. 

The procedure merges ultrasound with MRI images to give urologists a real-time, three-dimensional view of the prostate. Because the MRI images are analyzed by a radiologist prior to the biopsy, the urologist has a targeted approach to collecting tissue samples.

"Eisenhower is one of a few hospitals doing this procedure in the state of Georgia," said Army Lt. Col. (Dr.) Jennifer Pugliese, chief of Urology at Eisenhower Army Medical Center.

Other than skin cancer, prostate cancer is the most common cancer in American men, according to the American Cancer Society. For 2018, the Society estimates "about 164,690 new cases of prostate cancer will be diagnosed and there will be about 29,430 deaths from prostate cancer."

"About 1 man in 9 will be diagnosed with prostate cancer during his lifetime," according to ACS statistics. "Prostate cancer develops mainly in older men and in African-American men. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66."

The standard screening for prostate cancer, according to Pugliese, is a blood test that specifically measures PSA, or prostate serum antigen, and a digital rectal examination. Abnormal PSA levels may indicate the need for a prostate biopsy where, using ultrasound alone for guidance, tissue samples are taken with a biopsy needle that is passed through the ultrasound probe and rectal wall into the prostate. 

"Using a standard grid pattern, I'll take at least 12 samples," she said. This method returns a false negative result of 20 to 30 percent.

"The difference with the ultrasound/MRI fusion," Pugliese said, "is that I can better 'visualize' which areas of the prostate need to be sampled. This is a multidisciplinary approach with an experienced radiologist" who identifies and digitally marks the suspect tissue on the MRI before the actual biopsy.

The urologist moves the ultrasound probe around the prostate while the fusion software shifts the overlaid MRI image, already marked by the radiologist, giving the medical team a real-time, 3-D ultrasound/MRI view. They use the fused image to guide the biopsy needles precisely to the tissue indicated as suspicious, rather than poking around a pre-determined grid, hoping they find something.

"This is an exciting new approach that yields a lower false negative rate than standard template biopsy and has a higher likelihood of identifying clinically significant prostate cancer," Pugliese said. "It is simply a more accurate prostate biopsy." 

According to the ACS, "prostate cancer is the second leading cause of cancer death in American men, behind lung cancer. About 1 man in 41 will die of prostate cancer. 

"Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 2.9 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today."

The earlier prostate cancer is diagnosed, the better the long-term prognosis is for the patient and the more likely a curative treatment will be successful. Curative treatments can include radiation and surgery. Hormone therapy, immunotherapy and chemotherapy are typically reserved for advanced or metastatic prostate cancer. Active surveillance can even be offered to patients with low risk or very low risk disease, avoiding active treatment all together. 

Early and reliable diagnosis is key to sorting out the appropriate treatment and, thanks to the ultrasound/MRI fusion procedure, it's easier to get an accurate diagnosis sooner.

Disclaimer: Re-published content may have been edited for length and clarity. Read original post.

You also may be interested in...

Implementing Congressional Direction for Reform of the Military Health System

Policy

Policy Memorandum, signed by Deputy Secretary of Defense Patrick M. Shanahan, to direct implementation of the Military Health System (MHS) organizational reform required by the National Defense Authorization Act.

DHA IPM 18-008: Use of Medical Q Services (MQS) Contract by Military Treatment Facilities (MTFs)

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) through (d): - Instructs MTFs and servicing contracting offices to use the DHA MQS contracts for the procurement of health care staffing requirements for market segments of physician, nurse, dental, and ancillary contract services in the United States and its Territories. - Is effective immediately; it must be incorporated into a forthcoming change to DHA Procedural Instruction 6025.05 (Reference (g)). This DHA-IPM will expire effective 12 months from the date of issue.

DoD Instruction 1010.10: Health Promotion and Disease Prevention

Policy

This instruction reissues DoD Directive (DoDD) 1010.10 (Reference (a)) as a DoD instruction (DoDI) in accordance with the authority in DoDD 5124.02 (Reference (b)) to establish policy and assign responsibilities for health promotion and disease prevention in accordance with References (c) through (f).

  • Identification #: DoD Instruction 1010.10
  • Date: 4/28/2014
  • Type: Instructions
  • Topics: Preventive Health

Military Health System Prescription Transfer Procedures

Policy

Effective immediately, all Department of Defense (DoD) military treatment facility (MTF) outpatient pharmacies will accept patient requests for prescription transfers from another MTF and from retail pharmacies. When another pharmacy requests prescription transfer information on behalf of a patient, DoD MTF outpatient pharmacies will respond to the inquirer in a timely manner.

<< < 1 > >> 
Showing results 1 - 4 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing; Download a PDF Reader or learn more about PDFs.